NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has renewed and extended its development and production agreements with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, TABACOEX cooperative, Rosalejo, and OLIVOS DE BADAJOZ, Badajoz in Extremadura region of Spain. NOMAD is conducting these activities on behalf of NAMBAWAN Biotech GmbH, Munich, Germany, […]
continue readingNomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend their Research and Development Agreement
Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of research and early development of NOMAD’s R&D pipeline product candidates, including but not limited to, antibacterial proteins […]
continue readingNOMAD Bioscience receives patents in Japan and Australia for its antibacterials Salmocins
NOMAD Bioscience GmbH has announced that the patent offices of Japan and Australia have issued the decisions to grant patents for NOMAD’s patent applications ‘Bacteriocins for the control of Salmonella enterica, JP2019-551665 and AU2018239310.The patents cover NOMAD’s Salmocins, non-antibiotic antibacterial proteins and the company’s lead product candidates for food and feed safety and veterinary markets. The […]
continue readingNOMADS UAB, Lithuania Published a Milestone Research Paper Describing its Chimeric Bacteriocins for Control of Multidrug-Resistant Pseudomonas
NOMADS UAB, Lithuania, NOMAD Bioscience’s wholly owned subsidiary, announces publication in the Nature group journal Scientific Reports (Š. Paškevičius, V. Dapkutė, A. Misiūnas, M. Balzaris, P. Thommes, A. Sattar, Y. Gleba and A. Ražanskienė, “Chimeric bacteriocin S5-PmnH engineered by domain swapping efficiently controls Pseudomonas aeruginosa infection in murine keratitis and lung models” Sci Rep. 2022 April […]
continue readingNOMAD BIOSCIENCE Broadens Its Agreements with Research and Commercial Growers, Spain, to Conduct Pilot Field and Greenhouse Trials Aimed at Industrial Manufacturing of Its Protein Products
NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has renewed and extended its development and production agreements with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, Spain, TABACOEX cooperative, Rosalejo, and OLIVOS DE BADAJOZ cooperative, Badajoz in Extremadura region of Spain. In 2021, CTAEX and TABACOEX conducted first open field and greenhouse […]
continue readingNOMAD Bioscience Receives GRAS Regulatory Recognition by FEMA for Its Plant-Made Natural Thaumatin II as a Flavour Modifier/Enhancer
NOMAD Bioscience GmbH received a formal GRAS recognition letter from the Flavor and Extract Manufacturers Association (FEMA) in response to NOMAD’s GRAS application describing use of plant-expressed Thaumatin II as a flavour modifier/enhancer (FEMA GRAS 5010). FEMA’s expert panel has affirmed Thaumatin II as a GRAS substance that can be safely used in a wide […]
continue readingProf. Dr. Yuri (Jurijus) Gleba, CEO and majority shareholder of NOMAD Bioscience has supported Ukrainian Army by donating 100 thousand Euro to reinforce the defense against Russian aggression
Prof. Dr. Yuri (Jurijus) Gleba, renown scientist and entrepreneur, CEO and major shareholder of Nomad Bioscience GmbH, a German biotechnology company, has donated 100 thousand Euro to the Armed Forces of Ukraine to support the defense against Russian aggression. Prof. Gleba also pledged his future support and expressed his gratitude to all researchers and businessmen […]
continue reading
NOMAD Bioscience Extends Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Sweetener, Amendment GRN 910S
NOMAD Bioscience received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice amendment GRN 910S describing broader use of plant-produced Thaumatin II as sweetener. Thaumatin II is natural noncaloric high intensity sweetener under development at NOMAD. GRAS is a facilitated US regulatory marketing allowance pathway […]
continue readingNomad Bioscience and Fraunhofer Institute of Cell Therapy and Immunology Extend and Broaden their Research and Development Agreement
Nomad Bioscience GmbH, Munich, Germany (“NOMAD”) is pleased to announce that the Company has extended and broadened its research and development agreement (“Agreement”) with the Fraunhofer Institute of Cell Therapy and Immunology, Leipzig/Halle, Germany (“FRAUNHOFER”) that covers multiple areas of research and early development of NOMAD’s R&D pipeline product candidates, including but not limited to, […]
continue readingNOMAD Bioscience Receives Notice of Allowance from USPTO for Its Patent Application ‚Bacteriocins for control of Salmonella enterica‘
NOMAD has announced that the United States’ Patent and Trademark Office (USPTO) has issued the "Notice of Allowance" for the NOMAD’s patent application “Bacteriocins for control of Salmonella enterica”, U.S. Appl. No. 16/577,484. All filed claims of the application necessary for a broad protection have been allowed. This is the second issued U.S. patent that […]
continue reading